| Sep 30 |
KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema
|
| Sep 26 |
KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)
|
| Sep 10 |
KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
|
| Sep 10 |
KalVista Pharmaceuticals appoints Brian Piekos as finance chief
|
| Sep 10 |
KalVista Appoints Brian Piekos as Chief Financial Officer
|
| Sep 8 |
Earnings week ahead: Adobe, Oracle, Kroger, GameStop and more
|
| Sep 6 |
KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024
|
| Sep 5 |
KalVista Pharmaceuticals: Looking To Be A Major Player In HAE
|
| Sep 5 |
KalVista Pharmaceuticals GAAP EPS of -$0.87 beats by $0.11
|
| Sep 5 |
KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
|
